Villebon sur Yvette, France

Julie Rivollier



 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Julie Rivollier: Innovator in Cancer Treatment

Introduction

Julie Rivollier is a prominent inventor based in Villebon sur Yvette, France. She has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutic agents for serious health conditions. With a total of 3 patents to her name, her work focuses on innovative solutions for treating cancer, viral infections, and lung diseases.

Latest Patents

Rivollier's latest patents include groundbreaking research on derivatives of indole. These compounds are designed to have a specific MKlp2 inhibition profile, making them useful as therapeutic agents. Her inventions aim to provide new treatment options for patients suffering from cancer, viral infections, and lung diseases.

Career Highlights

Throughout her career, Julie has worked with notable organizations such as Biokinesis and the Centre National de la Recherche Scientifique. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community significantly.

Collaborations

Julie has collaborated with esteemed colleagues, including Catherine Guillou and Julien Rouleau. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to impactful discoveries.

Conclusion

Julie Rivollier's work exemplifies the spirit of innovation in the medical field. Her dedication to developing new therapeutic agents showcases her commitment to improving patient outcomes. Through her patents and collaborations, she continues to make a lasting impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…